

**Supporting Information: The impact of whole human blood on the
kinetic inertness of platinum(IV) prodrugs – an HPLC-ICP-MS
study**

Sarah Theiner^a, Márkó Grabarics^b, Luis Galvez ^a, Hristo P. Varbanov^c, Nadine S.
Sommerfeld^c, Mathea S. Galanski^c, Bernhard K. Keppler^{c,d}, Gunda Koellensperger^{a*}

^a Institute of Analytical Chemistry, University of Vienna, Waehringer Strasse 38,
1090 Vienna, Austria

^b Department of Pharmacognosy, Semmelweis University, Üllői út 26, 1085 Budapest,
Hungary

^c Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, 1090
Vienna, Austria

^d Research Cluster ‘Translational Cancer Therapy Research’, University of Vienna,
Waehringer Strasse 42, 1090 Vienna, Austria

Table S1. ICP-MS operation parameters for direct infusion ICP-MS and RP-ICP-MS analysis.

	Direct infusion ICP-MS	RP-ICP-MS
ICP-MS system	Agilent 7500ce	Agilent 8800
	ICP-MS	ICP-MS/MS
Cone material	Nickel	Platinum
RF power [W]	1550	1550
Plasma Ar gas flow rate [L min ⁻¹]	15	15
Auxiliary Ar gas flow rate [L min ⁻¹]	0.90	0.90
Carrier Ar gas flow rate [L min ⁻¹]	1.05	0.70
Option O ₂ gas flow rate [L min ⁻¹]	-	0.20
Measured isotopes	¹⁹⁵ Pt and ¹⁸⁵ Re	¹⁹⁵ Pt
Integration time [s]	0.3 and 0.1	0.1
number of replicates	10	-

Table S2. Chromatographic conditions for RP-ICP-MS analysis.

Eluent flow rate [$\mu\text{L min}^{-1}$]	250
Injection volume [μL]	5
Gradient elution:	
Eluent:	
A	H ₂ O with 0.1 % (v/v) HCOOH
B	MeOH with 0.1 % (v/v) HCOOH
Gradient program:	
Time:	
0.0 min	100% A; 0% B
2.5 min	100% A; 0% B
10.5 min	10% A; 90% B
14.5 min	10% A; 90% B
14.6 min	100% A; 0% B
22.5 min	100% A; 0% B